. The latest vaccine is being developed by the British company Benchmark, which has a global market of around 8.5 million cats. It is being marketed in the United Kingdom and Europe as a ‘superfluous’ vaccination. The new vaccine is called HypoCat, and is being tested in the United States by Dr.